Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters

SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) — Cellics Therapeutics, Inc. (Cellics) announced today that results of the study that evaluates the potential benefits of macrophage and pulmonary epithelial nanosponges in neutralizing SARS-CoV-2 infectivity have been published in Nano Letters, entitled Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity, based on research conducted by its founder, Liangfang Zhang, Ph.D. http://pubs.acs.org/doi/abs/10.1021/acs.nanolett.0c02278